These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17938193)

  • 41. Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis.
    Kubendiran G; Paramasivan CN; Sulochana S; Mitchison DA
    J Chemother; 2006 Dec; 18(6):617-23. PubMed ID: 17267339
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach.
    Pienaar E; Sarathy J; Prideaux B; Dietzold J; Dartois V; Kirschner DE; Linderman JJ
    PLoS Comput Biol; 2017 Aug; 13(8):e1005650. PubMed ID: 28817561
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo.
    Veziris N; Truffot-Pernot C; Aubry A; Jarlier V; Lounis N
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3117-22. PubMed ID: 14506018
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay.
    Kambli P; Ajbani K; Sadani M; Nikam C; Shetty A; Udwadia Z; Rodwell TC; Catanzaro A; Rodrigues C
    Tuberculosis (Edinb); 2015 Mar; 95(2):137-41. PubMed ID: 25522842
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.
    Veziris N; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4015-9. PubMed ID: 16189074
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.
    Chan CY; Au-Yeang C; Yew WW; Leung CC; Cheng AF
    Antimicrob Agents Chemother; 2004 Jan; 48(1):340-3. PubMed ID: 14693563
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
    Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
    J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window.
    Firsov AA; Lubenko IY; Smirnova MV; Strukova EN; Zinner SH
    Antimicrob Agents Chemother; 2008 Jun; 52(6):1924-8. PubMed ID: 18378704
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors.
    Reuveni D; Halperin D; Fabian I; Tsarfaty G; Askenasy N; Shalit I
    Biochem Pharmacol; 2010 Apr; 79(8):1100-7. PubMed ID: 20025849
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.
    Nosova EY; Bukatina AA; Isaeva YD; Makarova MV; Galkina KY; Moroz AM
    J Med Microbiol; 2013 Jan; 62(Pt 1):108-113. PubMed ID: 23019190
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model.
    Allen GP; Kaatz GW; Rybak MJ
    Int J Antimicrob Agents; 2004 Aug; 24(2):150-60. PubMed ID: 15288314
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
    Lounis N; Bentoucha A; Truffot-Pernot C; Ji B; O'Brien RJ; Vernon A; Roscigno G; Grosset J
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3482-6. PubMed ID: 11709328
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis.
    Rodríguez JC; Ruiz M; Climent A; Royo G
    Int J Antimicrob Agents; 2001 Mar; 17(3):229-31. PubMed ID: 11282270
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Mutant prevention concentrations of fluoroquinolones for Staphylococcus aureus].
    Cui JC; Liu YN; Wang R; Liang BB; Pei F; Zheng ZJ
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1863-6. PubMed ID: 15631794
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
    Rodríguez JC; Ruiz M; López M; Royo G
    Int J Antimicrob Agents; 2002 Dec; 20(6):464-7. PubMed ID: 12458143
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.
    Malik M; Drlica K
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2842-4. PubMed ID: 16870782
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.
    Li SY; Tasneen R; Tyagi S; Soni H; Converse PJ; Mdluli K; Nuermberger EL
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630203
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model.
    Cremades R; Rodríguez JC; García-Pachón E; Galiana A; Ruiz-García M; López P; Royo G
    J Antimicrob Chemother; 2011 Oct; 66(10):2281-3. PubMed ID: 21733966
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of Haemophilus influenzae.
    Hedlin P; Blondeau JM
    Eye Contact Lens; 2007 May; 33(3):161-4. PubMed ID: 17502752
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Susceptibility of oral obligate anaerobes to telithromycin, moxifloxacin and a number of commonly used antibacterials.
    Tomás I; Tomás M; Alvarez M; Velasco D; Potel C; Limeres J; Diz P
    Oral Microbiol Immunol; 2007 Oct; 22(5):298-303. PubMed ID: 17803626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.